- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04341467
Amisulpride Treatment for BPSD in AD Patients
Amisulpride Versus Olanzapine Treatment for Behavioral and Psychological Symptoms in Patients With Dementia of the Alzheimer Type:A Randomized, Open-label, Prospective Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300222
- Recruiting
- Tianjin Anding Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- It conforms to the diagnostic standard of Alzheimer's disease in International Classification of Diseases 10th Revision (ICD-10)
- a total score of MMSE<24
- The patients had active behavioral symptoms with a minimum score of 20 on the 12-point Neuropsychiatric Inventory (NPI)
- Participant or guardian has to sign informed consent. The patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised
Exclusion Criteria:
- People with vascular dementia, frontotemporal dementia, dementia with Lewy bodies or other neurocognitive disorders;
- Patients with severe brain organic diseases or brain trauma;
- Physical illnesses associated with severe respiratory, circulatory, immune, and endocrine systems;
- History of other mental disorders;
- Those who are allergic to amisulpride or olanzapine;
- Patients who are contraindicated with amisulpride and olanzapine: pheochromocytoma, prolactin-dependent tumors and narrow-angle glaucoma;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amisulpride group
The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
|
The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
Other Names:
|
Active Comparator: Olanzapine group
The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
|
The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of neuropsychiatric inventory(NPI)scores
Time Frame: baseline, Week 2,4, and 8
|
The change from baseline neuropsychiatric inventory (NPI) items at week 2,4,and 8. Assess the frequency and severity of psychiatric symptoms, including delusions, hallucinations, aggression attacks, depression, anxiety, elevated emotions, indifferent emotions, de-inhibition, agitation, abnormal behaviors, sleep / night behaviors, appetite / eating disorders,the maximum scores is 144.The higher score are considered the psychiatric symptoms more serious.
|
baseline, Week 2,4, and 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of Clinical global impression-Severity of Illness (CGI-SI) score
Time Frame: baseline, Week 2,4, and 8
|
The change from baseline Clinical global impression-Severity of Illness (CGI-SI) score. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen The change from baseline Clinical global impression-Severity of Illness (CGI-SI) score. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen |
baseline, Week 2,4, and 8
|
Changes of Clinical global impression- global improvement (CGI-GI)
Time Frame: baseline, Week 2,4, and 8
|
The change from baseline Clinical global impression- global improvement (CGI-GI) items at week 2,4,and 8. The highest score is 7 points. A higher score indicates a more serious disease or a tendency to worsen |
baseline, Week 2,4, and 8
|
Changes of Mini-Mental State Examination(MMSE) scores.
Time Frame: baseline, Week 2,4, and 8
|
The change from baseline Mini-Mental State Examination(MMSE) items at week 2,4,and 8.The content includes time orientation, location orientation, immediate memory of language, attention and calculation, short-term memory, physical naming, language repeating, reading comprehension, speech expression and graphic description.
0 to 30 points, the lower the score, the more severe the cognitive impairment.
|
baseline, Week 2,4, and 8
|
Changes of Caregiver Burden Inventory (CBI) scores
Time Frame: baseline, Week 2,4, and 8
|
The change from baseline Caregiver Burden Inventory (CBI) items at week 2,4,and 8.The questionnaire contains 5 dimensions: time-dependent burden, development-restricted burden, physical burden, social burden, and emotional burden.
The total score is 96 points.
The higher the score, the heavier the burden.
|
baseline, Week 2,4, and 8
|
Treatment Emergent Symptom Scale (TESS)
Time Frame: Week 2,4, and 8
|
The scale collection includes 33 items of consciousness disorder, constipation, tremor, etc., to assess the adverse drug reactions and their severity.This table is used to evaluate 33 items of common consciousness disorder, constipation, tremor, etc. based on the adverse drug reactions.
Each item is scored according to the severity of the adverse drug reactions.
This scale does not need to be evaluated at baseline.
|
Week 2,4, and 8
|
Rating scale for extrapyramidal side effects (RSESE)
Time Frame: baseline, Week 2,4, and 8
|
Assessment of extrapyramidal reactions and their severity at various time points.Assess the severity of 9 aspects of gait, falling arms, shaking shoulders, elbow rigidity, fixed posture or wrist rigidity, leg swings, head and neck movements, tapping between eyebrows, drooling,The total score is 36 points.
The higher the score, the more severe extrapyramidal side effects.
|
baseline, Week 2,4, and 8
|
Abnormal Involuntary Movement Scale (AIMS)
Time Frame: baseline, Week 2,4, and 8
|
Assesses whether patients have involuntary movements and their severity in the face, limbs, and trunk at various time points.Assess facial movements, body movements, and trunk movements for involuntary movements and severity.
A total score of 2 or more is masculine gender.
|
baseline, Week 2,4, and 8
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Tauopathies
- Dementia
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Dopamine Antagonists
- Antidepressive Agents, Second-Generation
- Olanzapine
- Amisulpride
Other Study ID Numbers
- AMI-2019-BPSD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BPSD
-
BaycrestOntario Ministry of Health and Long Term CareTerminatedDementia | BPSDCanada
-
University of FloridaUS Department of Veterans AffairsCompletedDementia | BPSDUnited States
-
University of CopenhagenRegion Capital Denmark; Velux Fonden; Danish College of General PractitionersCompletedDementia | Antidepressive Agents | BPSD | DeprescriptionsDenmark
-
Soroka University Medical CenterUnknown
-
Brigham and Women's HospitalUniversity of California, Davis; University of South Carolina; Society and Health... and other collaboratorsRecruitingBehavioral and Psychological Symptoms of Dementia (BPSD)Thailand
-
University of Maryland, BaltimorePenn State UniversityCompletedDementia | Behavioral and Psychological Symptoms of Dementia (BPSD)United States
-
The University of Hong KongNot yet recruitingDepressive Symptoms | BPSD | Expressed Emotion
-
Clinica Luganese MoncuccoCompletedBPSD (Behavioral and Psycological Symptoms of Dementia)Switzerland
Clinical Trials on Amisulpride
-
Acacia Pharma LtdCompletedRenal Disease, End StageUnited States
-
Seoul National University HospitalUnknownSchizophreniaKorea, Republic of
-
CHA UniversityHandok Inc.UnknownSchizophrenia | Schizophreniform Disorder
-
Mclean HospitalNational Institute of Mental Health (NIMH)Completed
-
Kaohsiung Kai-Suan Psychiatric HospitalTerminated
-
Qilu Pharmaceutical (Hainan) Co., Ltd.Not yet recruiting
-
SanofiCompleted
-
University of California, Los AngelesPoloMar Health LLCNot yet recruiting